Literature DB >> 17337274

The incomplete nature of multiple sclerosis relapse resolution.

Fred D Lublin1.   

Abstract

Relapsing-remitting multiple sclerosis (RRMS) is often associated with accrual of disability, even though it precedes the progressive phase of the disease, in which clinical disability is most apparent. Changes in T1 and T2 magnetic resonance imaging (MRI) findings, as well as clinical trials of drugs that target RRMS, have established correlations between relapse episodes and disability progression. Briefly reviewed herein are relevant data that link relapses with disability accrual, including a recent direct analysis of well-defined clinical trial databases that shows MS relapses to have a measurable and sustained effect on disability. These studies pinpoint the measurable residual deficits of relapses that had, up to this point, only been implied by prior research, confirming the existence of relapse-associated step-wise worsening in patients with RRMS and lending credence to the continued development of long-term treatment targeted at the early phases of the disorder.

Entities:  

Mesh:

Year:  2007        PMID: 17337274     DOI: 10.1016/j.jns.2007.01.062

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  7 in total

1.  Emergency Department MRI Scanning of Patients with Multiple Sclerosis: Worthwhile or Wasteful?

Authors:  J Pakpoor; D Saylor; I Izbudak; L Liu; E M Mowry; D M Yousem
Journal:  AJNR Am J Neuroradiol       Date:  2016-10-06       Impact factor: 3.825

2.  Management of acute exacerbations in multiple sclerosis.

Authors:  Daniel Ontaneda; Alex D Rae-Grant
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

3.  Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials.

Authors:  Tobias Derfuss; Daniel Ontaneda; Jacqueline Nicholas; Xiangyi Meng; Kathleen Hawker
Journal:  Mult Scler Relat Disord       Date:  2016-05-24       Impact factor: 4.339

4.  The multiple sclerosis rating scale, revised (MSRS-R): development, refinement, and psychometric validation using an online community.

Authors:  Paul Wicks; Timothy E Vaughan; Michael P Massagli
Journal:  Health Qual Life Outcomes       Date:  2012-06-18       Impact factor: 3.186

5.  Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis.

Authors:  M S Freedman; C Metzig; L Kappos; C H Polman; G Edan; H-P Hartung; D H Miller; X Montalban; J Yarden; L Spector; E Fire; N Dotan; S Schwenke; V Lanius; R Sandbrink; C Pohl
Journal:  Mult Scler       Date:  2011-12-19       Impact factor: 6.312

6.  Longitudinal changes in the expression of IL-33 and IL-33 regulated genes in relapsing remitting MS.

Authors:  Subramaniam Sriram; Guzel Shaginurova; John T Tossberg; Chandramohan Natarajan; Charles F Spurlock; Thomas M Aune
Journal:  PLoS One       Date:  2018-12-18       Impact factor: 3.240

Review 7.  Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis.

Authors:  Stanley Cohan
Journal:  Biologics       Date:  2016-09-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.